van Linschoten, Reinier C. A.
Jansen, Fenna M.
Pauwels, Renske W. M.
Smits, Lisa J. T.
Atsma, Femke
Kievit, Wietske
de Jong, Dirk J.
de Vries, Annemarie C.
Boekema, Paul J.
West, Rachel L.
Bodelier, Alexander G. L.
Gisbertz, Ingrid A. M.
Wolfhagen, Frank H. J.
Römkens, Tessa E. H.
Lutgens, Maurice W. M. D.
van Bodegraven, Adriaan A.
Oldenburg, Bas
Pierik, Marieke J.
Russel, Maurice G. V. M.
de Boer, Nanne K.
Mallant-Hent, Rosalie C.
ter Borg, Pieter C. J.
van der Meulen-de Jong, Andrea E.
Jansen, Jeroen M.
Jansen, Sita V.
Tan, Adrianus C. I. T. L.
van der Woude, C. Janneke
Hoentjen, Frank
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
https://doi.org/10.1007/s10620-024-08410-z
Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study (Results)
https://doi.org/10.1136/bmjopen-2019-035326
Funding for this research was provided by:
ZonMw (848015002)
Article History
Received: 8 December 2023
Accepted: 26 March 2024
First Online: 9 April 2024
Declarations
:
: FMJ has received a research grant from ZonMW. DJdJ has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Galapagos and held leadership roles in the Dutch Initiative on Crohn and Colitis and the IBD workgroup of the Dutch Gastroenterology Society. ACdV has received research grants from Takeda, Janssen and Pfizer. RLW has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring, Pfizer, Galapagos, AbbVie and Janssen. TEHR payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie and has participated in the advisory board for Galapagos. MWMDL has received a grant for podcasts from Pfizer, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Jansen-Cilag and Galapagos, participated in advisory boards of BMS and Galapagos, and held leadership roles in the Elisabeth Twee Steden Ziekenhuis. AAvB has received research grants from Pfizer, Teva and ZonMW, consulting fees from Ferring, Galapagos, AbbVie and BMS, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring, Galapagos and Janssen, support for attending meetings from Janssen, and held leadership roles in committees of the Dutch Gastroenterology Society and National Federation of Medical Specialists. BO has received research grants from Galapagos, Takeda, Ferring and Celltrion, has received consulting fees from AbbVie, Galapagos, Pfizer, Ferring, Takeda and Janssen, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Takeda, Galapagos, AbbVie and Ferring and was chairman of the IBD committee of the Dutch Association of Gastroenterology (NVMDL). MJP has received consulting fees from Takeda, Janssen, Galapagos and AbbVie and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen. NKdB has served as a speaker for AbbVie, Takeda and MSD. He has served as consultant and principal investigator for Takeda and TEVA. He has received research grants from Dr. Falk, Takeda, TEVA and MLDS. All outside the submitted work.RMH has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ITS and is a member of the national IBD committee of the Dutch Association for Gastroenterology and Hepatology. AEvdMdJ has received research grants from Galapagos, nestle, Cablon and Norgine, has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Galapagos, Tramedico and Janssen-Cilag, and has participated in an advisory board for Ferring. CJvdW has received funding for the present study from ZonMW, has received research grants from ZonMW, Falk and Pfizer, has received consulting fees from Janssen, Galapagos, and Pfizer, has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring and AbbVie and had leadership roles in the European Crohn’s & Colitis organisation, United European Gastroenterology council and the Dutch Association for Gastroenterology (NVGE). FH has received funding for the present study from ZonMW, has received research grants from Janssen, AbbVie, Pfizer and Takeda, and has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Janssen, Takeda and Pfizer. RCAvL, RWMP, LJTS, FA, WK, PJB, AGLB, IAMG, FHJW, MGVMR, PCJtB, JMJ, SVJ, ACIATLT has nothing to disclose.
: The study protocol was approved by the Medical Ethical Review Committee of the Radboud University Medical Centre (registration number NL58948.091.16). Written informed consent was obtained from each patient who participated in the study.